180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has published a preclinical study report on the effects of cannabigerol (“CBG”) derivatives on pain, inflammation and obesity. The report was published in the “Molecules” journal. ATNF has worked closely with cannabinoid medicinal chemistry expert Prof. Raphael Mechoulam and team at Hebrew University (“HU”) in Jerusalem as well biologists at HU and Oxford University. According to the company, the study discusses the synthesis of three novel CBG derivative compounds as well as their impact on traditional preclinical models of pain, inflammation and obesity. The study noted that all three demonstrated robust anti-inflammatory and analgesic properties with one — HUM-234 — showing ability to prevent weight gain in mice that were eating a high-fat diet and abrogated the development of fatty liver. Fatty liver, or steatosis, is often associated with multiple metabolic disorders, such as diabetes and obesity, and can also be a precursor to liver fibrosis. “180 Life Sciences is focused on the treatment of inflammatory diseases using several different platforms, including new uses of anti-TNF antibodies that I pioneered with Dr. Woody, CEO of 180 Life Sciences,” said 180 Life Sciences cochair Professor Sir Marc Feldmann in the press release. “This new publication derives from a more than 20-year collaboration with my friend Prof. Raphael Mechoulam, the pioneer of cannabis chemistry. I believe these treatments have the potential to open up the field and expand the range of new patentable synthetic derivatives of cannabis, which are nonpsychoactive and have been shown in studies to be effective in pain and inflammation. We believe with this new molecule, metabolic disorders including the increasingly common fatty liver, a precursor of fibrosis, may be targeted. We are looking forward to working to develop this new family of therapeutics for use in treating multiple common unmet needs.”
To view the full report, visit https://ibn.fm/MGqqj
To view the full press release, visit https://ibn.fm/7pKRQ
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. The company’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.